JP2020535180A - 抗ｉｇｆ、抗ｐｆ−１の抗がん組み合わせ治療 - Google Patents

抗ｉｇｆ、抗ｐｆ−１の抗がん組み合わせ治療 Download PDF

Info

Publication number
JP2020535180A
JP2020535180A JP2020517814A JP2020517814A JP2020535180A JP 2020535180 A JP2020535180 A JP 2020535180A JP 2020517814 A JP2020517814 A JP 2020517814A JP 2020517814 A JP2020517814 A JP 2020517814A JP 2020535180 A JP2020535180 A JP 2020535180A
Authority
JP
Japan
Prior art keywords
compound
seq
antibody
cancer
igf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020517814A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020535180A5 (enExample
Inventor
ウルリケ ワイヤー−チェルニロフスキー
ウルリケ ワイヤー−チェルニロフスキー
マルクス レシュケ
マルクス レシュケ
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング, ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2020535180A publication Critical patent/JP2020535180A/ja
Publication of JP2020535180A5 publication Critical patent/JP2020535180A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2020517814A 2017-09-29 2018-09-28 抗ｉｇｆ、抗ｐｆ−１の抗がん組み合わせ治療 Pending JP2020535180A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17194196.6 2017-09-29
EP17194196 2017-09-29
PCT/EP2018/076494 WO2019063802A1 (en) 2017-09-29 2018-09-28 ANTICANCER ANTI-IGF POLY THERAPY, ANTI PD-1

Publications (2)

Publication Number Publication Date
JP2020535180A true JP2020535180A (ja) 2020-12-03
JP2020535180A5 JP2020535180A5 (enExample) 2021-11-11

Family

ID=60009481

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020517814A Pending JP2020535180A (ja) 2017-09-29 2018-09-28 抗ｉｇｆ、抗ｐｆ−１の抗がん組み合わせ治療

Country Status (5)

Country Link
US (1) US20200239559A1 (enExample)
EP (1) EP3687573A1 (enExample)
JP (1) JP2020535180A (enExample)
CN (1) CN111148534A (enExample)
WO (1) WO2019063802A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019021032A2 (pt) * 2017-04-05 2020-05-05 Boehringer Ingelheim Int terapia combinada anticâncer
CA3148291A1 (en) * 2019-09-11 2021-03-18 Boehringer Ingelheim Io Canada, Inc. Methods of treating cancer by the use of pd-1 axis inhibitors and anti-periostin antibodies
CN112111575B (zh) * 2020-09-22 2023-01-10 重庆医科大学附属第一医院 胰岛素样生长因子2在恶性肿瘤预后和治疗选择中的应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006340714A (ja) * 2005-05-09 2006-12-21 Ono Pharmaceut Co Ltd ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法
JP2012511315A (ja) * 2008-12-12 2012-05-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｇｆ抗体
WO2013060872A1 (en) * 2011-10-27 2013-05-02 Boehringer Ingelheim International Gmbh Anticancer combination therapy
JP2016511265A (ja) * 2013-03-07 2016-04-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新生物の治療のための併用療法
WO2016061142A1 (en) * 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
JP2017505311A (ja) * 2014-01-24 2017-02-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング エキセメスタン及びエベロリムスと組み合わせてインスリン様成長因子（ｉｇｆ）受容体アンタゴニストを用いる癌治療
JP2017506067A (ja) * 2014-01-24 2017-03-02 デイナ ファーバー キャンサー インスティチュート，イ Ｐｄ−１に対する抗体分子およびその使用
WO2017055291A1 (en) * 2015-09-28 2017-04-06 Boehringer Ingelheim International Gmbh Anticancer combination therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
PL2242773T3 (pl) 2008-02-11 2017-11-30 Cure Tech Ltd. Przeciwciała monoklonalne do leczenia nowotworu
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
JP2019509282A (ja) * 2016-02-29 2019-04-04 ファウンデーション・メディシン・インコーポレイテッド 癌の治療方法

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006340714A (ja) * 2005-05-09 2006-12-21 Ono Pharmaceut Co Ltd ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法
JP2012511315A (ja) * 2008-12-12 2012-05-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｇｆ抗体
WO2013060872A1 (en) * 2011-10-27 2013-05-02 Boehringer Ingelheim International Gmbh Anticancer combination therapy
JP2016511265A (ja) * 2013-03-07 2016-04-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新生物の治療のための併用療法
JP2017505311A (ja) * 2014-01-24 2017-02-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング エキセメスタン及びエベロリムスと組み合わせてインスリン様成長因子（ｉｇｆ）受容体アンタゴニストを用いる癌治療
JP2017506067A (ja) * 2014-01-24 2017-03-02 デイナ ファーバー キャンサー インスティチュート，イ Ｐｄ−１に対する抗体分子およびその使用
WO2016061142A1 (en) * 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
WO2017055291A1 (en) * 2015-09-28 2017-04-06 Boehringer Ingelheim International Gmbh Anticancer combination therapy

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CANCER RES, vol. Vol. 77 (13_Supplement), JPN6022039378, 1 July 2017 (2017-07-01), pages 20, ISSN: 0004877154 *
GASTROENTEROLOGY, vol. 151, JPN6022039380, 2016, pages 1192 - 1205, ISSN: 0004877153 *
MOL CANCER THER, vol. 13, no. 2, JPN6022039379, 2014, pages 399 - 409, ISSN: 0004877152 *
REGISTRY (STN) [ONLINE], JPN7022004464, 5 September 2022 (2022-09-05), ISSN: 0004877155 *
水島裕, 今日の治療薬（2003年版）, vol. 第25版, JPN6020025586, 15 February 2003 (2003-02-15), pages 149, ISSN: 0005032556 *

Also Published As

Publication number Publication date
US20200239559A1 (en) 2020-07-30
WO2019063802A1 (en) 2019-04-04
CN111148534A (zh) 2020-05-12
EP3687573A1 (en) 2020-08-05

Similar Documents

Publication Publication Date Title
US20240018257A1 (en) Antibodies specific to human poliovirus receptor (pvr)
JP6586087B2 (ja) Ｐｄ−１アンタゴニストとジナシクリブとの組合せでの癌治療
JP2023039448A (ja) がんを治療するための、ｐｄ－１アンタゴニスト及びｖｅｇｆｒ／ｆｇｆｒ／ｒｅｔチロシンキナーゼ阻害剤の組合せ
EP3344658B1 (en) Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
EP3102604B1 (en) Combination of a pd-1 antagonist and a 4-1bb agonist for treating cancer
US11198726B2 (en) Anti-cancer combination therapy
JP7274426B2 (ja) 抗ｇｉｔｒアゴニスト抗体での癌の処置
KR20180103150A (ko) 암을 치료하기 위한 ox40 작용제 및 4-1bb 작용제 단클론 항체의 조합
KR20170004006A (ko) 암을 치료하기 위한 항-ｃｃｒ4 항체 및 4-1ｂｂ 효능제의 조합
JP2022512851A (ja) がんの処置のための抗ｔｉｇｉｔ抗体の投薬レジメン
US20210317214A1 (en) Combination therapy of a pd-1 antagonist and lag3 antagonist for treating patients with non-microsatellite instability-high or proficient mismatch repair colorectal cancer
JP2020535180A (ja) 抗ｉｇｆ、抗ｐｆ−１の抗がん組み合わせ治療
KR102239752B1 (ko) 종양 특이적 약물복합체와 항pd-l1 항체를 유효성분으로 하는 암 예방 또는 치료를 위한 병용 투여용 약학 조성물
US20240010729A1 (en) Combination therapy of a pd-1 antagonist and lag3 antagonist and lenvatinib or a pharmaceutically acceptable salt thereof for treating patients with cancer
WO2024208253A1 (en) Compositions and methods for treating solid tumors with anti-btla as combination therapy
US20230322929A1 (en) Compositions and Methods for Treating Solid Tumors with Anti-BTLA as Mono or Combination Therapy
WO2025128499A1 (en) Combination therapy of a pd-1 antagonist and lag3 antagonist and all-trans retinoic acid or a pharmaceutically acceptable salt thereof for treating patients with cancer
HK40079353A (en) Antibodies specific to human poliovirus receptor (pvr)
KR20230087451A (ko) 암 환자를 치료하기 위한 pd-1 길항제 및 vegfr-2에 대한 길항제의 조합 요법
CN116806226A (zh) 用于治疗癌症患者的pd-1拮抗剂和vegfr-2的拮抗剂的联合疗法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210927

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220920

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230410